• 6767 Bertner Ave, Mitchell Basic Science Research Building

    77030 Houston

    United States

  • 6465 Citations
  • 39 h-Index
20012019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 10 Similar Profiles
Neoplasms Medicine & Life Sciences
Mutation Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Clinical Trials, Phase I Medicine & Life Sciences
Survival Medicine & Life Sciences
Non-Small Cell Lung Carcinoma Medicine & Life Sciences
Phosphatidylinositol 3-Kinases Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2001 2019

Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial

Juric, D., Janku, F., Rodon Ahnert, J., Burris, H. A., Mayer, I. A., Schuler, M., Seggewiss-Bernhardt, R., Gil-Martin, M., Middleton, M. R., Baselga, J., Bootle, D., Demanse, D., Blumenstein, L., Schumacher, K., Huang, A., Quadt, C. & Rugo, H. S., Feb 1 2019, In : JAMA Oncology. 5, 2

Research output: Contribution to journalArticle

Estrogen Receptors
Clinical Trials
Breast Neoplasms
Maximum Tolerated Dose
Phosphatidylinositol 3-Kinase

Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden

Liang, W. S., Vergilio, J. A., Salhia, B., Huang, H. J., Oki, Y., Garrido-Laguna, I., Park, H., Westin, J. R., Meric-Bernstam, F., Fabrizio, D., Miller, V. A., Stephens, P. J., Fanale, M. A., Ross, J. S. & Janku, F., Feb 1 2019, In : Oncologist. 24, 2, p. 219-228 10 p.

Research output: Contribution to journalArticle

Hodgkin Disease
Mutation
Genes
Plasma Cells
Gene Frequency

Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies

Bhatty, M., Kato, S., Piha-Paul, S. A., Naing, A., Subbiah, V., Huang, H. J., Karp, D. D., Tsimberidou, A. M., Zinner, R. G., Hwu, W-J., Javle, M., Patel, S. P., Hu, M. I-N., Varadhachary, G. R., Conley, A. P., Ramzanali, N. M., Holley, V. R., Kurzrock, R., Meric-Bernstam, F., Kwang Chae, Y. & 3 othersKim, K. B., Falchook, G. S. & Janku, F., Feb 1 2019, In : Cancer. 125, 3, p. 463-472 10 p.

Research output: Contribution to journalArticle

Carboplatin
Paclitaxel
Melanoma
Mitogen-Activated Protein Kinase Kinases
Neoplasms

Advances on the BRAF front in colorectal cancer

Janku, F., Apr 1 2018, In : Cancer Discovery. 8, 4, p. 389-391 3 p.

Research output: Contribution to journalArticle

Mitogen-Activated Protein Kinase Kinases
Colorectal Neoplasms
Proteins
Therapeutics